

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 13:55:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      573 TO ITERATE

100.0% PROCESSED      573 ITERATIONS                              14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        10024 TO    12896
PROJECTED ANSWERS:              56 TO      504

L5           14 SEA SSS SAM L4

=> d scan

L5   14 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-
     [[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-,
     (2E)-2-butenedioate (1:2) (9CI)
MF   C28 H48 N4 O5 S . 2 C4 H4 O4

     CM   1
```

PAGE 1-A



PAGE 1-B



CM 2

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l4 full
FULL SEARCH INITIATED 13:55:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10975 TO ITERATE

100.0% PROCESSED 10975 ITERATIONS 292 ANSWERS
SEARCH TIME: 00.00.01

L6 292 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 357.18 357.39

FILE 'CAPLUS' ENTERED AT 13:56:03 ON 12 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 11 Mar 2008 (20080311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L7 11 L3

=> s l3(l)ract+nt/rl
11 L3
3084775 RACT+NT/RL (10 TERMS)
L8 7 L3(L)RACT+NT/RL

=> s l6
L9 3 L6

=> s l6(l)prep+nt/rl
3 L6

```
       4542169 PREP+NT/RL  (18 TERMS)
L10          3 L6(L)PREP+NT/RL

=> s l3 and l6
            11 L3
             3 L6
L11          3 L3 AND L6

=> s l7 and l9
L12          3 L7 AND L9

=> s l8 and l10
L13          3 L8 AND L10

=> d l13 1-3 ibib abs hitstr

L13  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:1392027  CAPLUS
DOCUMENT NUMBER:          148:54908
TITLE:                    Preparation of spirocyclic sulfonamides and related
                          compounds as modulators of bradykinin receptor
                          activity
INVENTOR(S):              Hodgetts, Kevin J.; Ihle, David C.; Li, Guiying; Ge,
                          Ping; Chenard, Bertrand L.; Wustrow, David J.
PATENT ASSIGNEE(S):       Neurogen Corporation, USA
SOURCE:                   PCT Int. Appl., 82pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007140383         A2    20071206    WO 2007-US69918         20070530
     WO 2007140383         A3    20080124
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       US 2006-803419P     P  20060530
OTHER SOURCE(S):          MARPAT 148:54908
GI
```



I



II

AB Title compds. I [Ar = (un)substituted Ph or heteroaryl; A = N, CH or C; B = N or CH; D = NR4a, CH(R4b), O, SO or SO2; Y = (CH2)rZ(CH2)p optionally substituted wherein r and p independently are chosen from 0-6 and Z = absent, O, S or NR6 where R6 = H or alkyl; R4a = H, (un)substituted alkyl, alkenyl, etc.; R4b = H, halo, CN, OH, etc.; R2 and R3 independently = H, (un)substituted alkyl, alkenyl, etc., or taken together from (un)substituted carbocycle or heterocycle; R5 independently at each occurrence = oxo or alkyl and can occur from 0-4 times; n independently = 1-3], and their pharmaceutically acceptable salts, are prepared and disclosed for modulating bradykinin receptor activity. Thus, e.g., II was prepared by sulfonation of 2-(methylamino)ethanol with 4-methoxy-2,6-dimethylphenylsulfonyl chloride, O-alkylation with tert-Bu bromoacetate, hydrolysis and amidation with 3-methyl-3,9-diazaspiro[5.5]undecane. I may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to B1 modulation in humans, domesticated companion animals and livestock animals, including inflammation and pain. Select compds. of the invention exhibit an IC50 at B1 that is 5 μM or less. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

IT 1001054-54-1P 1001054-55-2P 1001054-57-4P
1001054-58-5P 1001054-63-2P 1001054-67-6P
1001054-68-7P 1001054-70-1P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spirocyclic sulfonamides and related compds. as modulators of bradykinin receptor activity)

RN 1001054-54-1 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-(7-methyl-2,7-diazaspiro[3.5]non-2-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 1001054-55-2 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(2,8-diazaspiro[4.5]dec-2-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 1001054-57-4 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 1001054-58-5 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(2,6-diazaspiro[3.4]oct-2-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 1001054-63-2 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[2-(1-methylethyl)-2,8-diazaspiro[4.5]dec-8-yl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 1001054-67-6 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(2,7-diazaspiro[3.5]non-7-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 1001054-68-7 CAPLUS
CN Benzenesulfonamide, 2-chloro-4-methoxy-N-methyl-N-[2-[2-(9-methyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 1001054-70-1 CAPLUS
CN Benzenesulfonamide, 2,4-dichloro-N-[2-[2-(3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]-N-methyl- (CA INDEX NAME)



IT 959640-61-0P 959640-62-1P 959640-63-2P
959640-70-1P 959640-71-2P 959640-72-3P
959640-73-4P 959640-74-5P 959640-75-6P
959640-76-7P 959640-77-8P 959640-78-9P
959640-79-0P 959640-81-4P 959640-84-7P
959640-86-9P 959640-87-0P 959640-88-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spirocyclic sulfonamides and related compds. as modulators of bradykinin receptor activity)

RN 959640-61-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-(9-methyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 959640-62-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(2-cyclobutyl-2,8-diazaspiro[4.5]dec-8-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-63-2 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(8-cyclobutyl-2,8-diazaspiro[4.5]dec-2-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-70-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(9-cyclobutyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-71-2 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[9-(phenylmethyl)-3,9-diazaspiro[5.5]undec-3-yl]ethoxy]ethyl]- (CA INDEX NAME)



RN 959640-72-3 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-73-4 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(9-acetyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-74-5 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(9-ethyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-75-6 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(9-propyl-3,9-diazaspiro[5.5]undec-3-yl)ethoxy]ethyl]- (CA INDEX NAME)



RN 959640-76-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[9-(1-methylethyl)-3,9-diazaspiro[5.5]undec-3-yl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 959640-77-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-2,6-dimethoxy-N-methyl-N-[2-[2-(9-methyl-3,9-diazaspiro[5.5]undec-3-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 959640-78-9 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[2-[2-(2-cyclobutyl-2,8-diazaspiro[4.5]dec-8-yl)-2-oxoethoxy]ethyl]-4,6-dimethoxy-N-methyl- (CA INDEX NAME)



RN 959640-79-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-(2-methyl-2,8-diazaspiro[4.5]dec-8-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 959640-81-4 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 959640-84-7 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[3-(cyanomethyl)-3,9-diazaspiro[5.5]undec-9-yl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 959640-86-9 CAPLUS
CN 3-Azaspiro[5.5]undecane-9-carboxylic acid, 3-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, ethyl ester (CA INDEX NAME)



RN 959640-87-0 CAPLUS
CN 3-Azaspiro[5.5]undecane-9-carboxamide, 3-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl- (CA INDEX NAME)



RN 959640-88-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[9-[(dimethylamino)methyl]-3-azaspiro[5.5]undec-3-yl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



IT 766558-33-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of spirocyclic sulfonamides and related compds. as modulators of bradykinin receptor activity)

RN 766558-33-2 CAPLUS
CN Acetic acid, 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]- (CA INDEX NAME)



L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857596 CAPLUS
DOCUMENT NUMBER: 141:350198
TITLE: Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
FR 2853648	A1	20041015	FR 2003-4530	20030411
FR 2853648	B1	20060818		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
IN 2005DN03814	A	20070817	IN 2005-DN3814	20050826
US 2006178360	A1	20060810	US 2005-549546	20050914
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.:
FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:350198
GI





II

AB The invention relates to novel heterocyclic benzenesulfonamide compds. I, a method for their preparation, and their therapeutic use and compns. [wherein: R1, R2, R3, R4 = H, halo, alkyl, alkoxy, CF3, or OCF3; Ra = alkyl; Y = saturated C2-5 alkylene optionally interrupted by O, unsatd. C2-4 alkylene, CH2CONHCH2; X = CH or N; p = 2 or 3; A = bond, NH, NMe, (un)branched C1-5 alkylene optionally bearing OH or an oxo group; provided that A and X together ≠ N; B = N-containing heterocycle or an amine group optionally substituted by 1 or 2 C1-4 alkyl groups; including salts with acids]. The compds. are useful as analgesics and antiinflammatories, particularly for severe pain. Approx. 150 compds. were prepared For instance, 2,6-dimethyl-4-methoxybenzenesulfonyl chloride was amidated with 2-(methylamino)ethanol, (100%), followed by etherification of the free alc. with tert-Bu bromoacetate (94%), deprotection of the tert-Bu ester with TFA (95%), and amidation of the resulting acid with 1-[2-(1-pyrrolidinyl)ethyl]piperazine using a resin-bound diimide reagent and HOAT (13%), to give invention compound II, isolated as the bis(trifluoroacetate). In a formaldehyde-based biphasic pain response test in mice, one compound gave 43% inhibition of 2nd-phase pain at 3 mg/kg orally, and another gave 40% inhibition at 1 mg/kg orally. In a bradykinin B1 receptor assay using human umbilical cord, compds. I had pKB values of 7.5 to 9.2.

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate, resolution; preparation of piperazine- and piperidine-containing
benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-09-2 CAPLUS

CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



IT 766558-14-9P, N-[2-[2-[4-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-14-9 CAPLUS

CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-11-6P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 766558-25-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775286-20-9P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide 775286-41-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-57-5P,

N-[2-[2-(4-Amino-1-piperidinyl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 775287-58-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-11-6 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 766558-25-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-20-9 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-41-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 775287-57-5 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775287-58-6 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N,2,4,6-tetramethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bis(trifluoroacetate) 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bis(trifluoroacetate) 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bis(trifluoroacetate) 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(dimethylamino)propyl]piperazine bis(trifluoroacetate) 766558-26-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 766558-28-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfona

mide fumarate 766558-30-9P, 1-(1-Azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1H-1,4-diazepine fumarate 775285-46-6P, N-[2-[2-[4-[3-(1-Azetidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-48-8P, N-[2-[2-[4-(1-Methyl-3-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-50-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-cyclopropyl-2,6-dimethylbenzenesulfonamide difumarate 775285-52-4P, N-[2-[2-[4-[2-(1-Pyrrolidinyl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-cyclopropyl-2,6-dimethylbenzenesulfonamide difumarate 775285-54-6P, N-[2-[2-[4-[(1-Methyl-2-imidazolyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-56-8P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-58-0P, N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-60-4P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-62-6P, N-[2-[2-[4-[3-(1-Pyrrolidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-64-8P, N-[2-[2-[4-[3-(1-Pyrrolidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-cyclopropyl-2,6-dimethylbenzenesulfonamide difumarate 775285-66-0P, N-[2-[2-[4-(8-Cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-68-2P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-70-6P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-cyclopropyl-2,6-dimethylbenzenesulfonamide difumarate 775285-72-8P, N-[2-[2-[4-(1-Cyclopropyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-74-0P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-78-4P, N-[2-[2-[4-[1-(1,1-Dimethylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-80-8P, N-[2-[2-[4-[(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-82-0P, N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-84-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-85-3P, N-[2-[2-[4-[2-(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-87-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)hexahydro-1H-1,4-diazepin-1-yl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-89-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-91-1P, N-[2-[2-[4-[1-(1-Methylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-93-3P, N-[2-[2-[4-[3-(1-Piperidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-95-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-

piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methoxy-N-methylbenzenesulfonamide difumarate 775285-97-7P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide fumarate 775285-99-9P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dichlorobenzenesulfonamide fumarate 775286-01-6P, N-[2-[2-[4-(1,2,2,6,6-Pentamethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-03-8P, N-[2-[2-[4-[3-(4-Methyl-1-piperazinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-05-0P, N-[2-[2-[4-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-07-2P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-09-4P, N-[2-[2-[4-[8-(1-Methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-11-8P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)-3-oxopropyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-13-0P, N-[2-[2-[4-[2-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifumarate 775286-15-2P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-cyclopropyl-2,6-dimethylbenzenesulfonamide difumarate 775286-17-4P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775286-19-6P, N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-21-0P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide difumarate 775286-22-1P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide 775286-23-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide difumarate 775286-24-3P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide 775286-25-4P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide difumarate 775286-26-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide 775286-27-6P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate 775286-28-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-2,3,6-trimethyl-N-methylbenzenesulfonamide 775286-29-8P, 4-Methoxy-N,2,3,6-tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-30-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-31-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-32-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide difumarate 775286-34-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775286-35-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-36-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-

[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775286-38-9P, N-[2-[2-[4-[2-(Dimethylamino)-1,1-dimethylethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775286-40-3P, N-[2-[2-[4-[2-(Dimethylamino)-1-hydroxyethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775286-42-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-44-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-46-9P, N-Cyclopropyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-48-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-50-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-(1-methylethyl)-1-piperazinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-52-7P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-54-9P, N-Cyclopropyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-56-1P, N-[2-[2-[4-[2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-58-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-[methyl(1-methylethyl)amino]ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-60-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(1-methyl-4-piperidinyl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-62-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1-(1-methylethyl)-4-piperidinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-64-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-ethyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-66-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-70-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-72-1P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-74-3P, N-[2-[2-[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-76-5P, N-Cyclopropyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-78-7P, 2,4-Dichloro-N,3-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-80-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-82-3P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-84-5P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-86-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-pyrrolidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-88-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-ethyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-90-3P, N-Cyclopropyl-4-methoxy-2,6-dimethyl-N-[2-

[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-
oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-92-5P,
N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-
1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775286-94-7P, N-Methyl-4-methoxy-2,6-dichloro-N-[2-[2-[4-[(4-
methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-
oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-96-9P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-
1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate
775286-98-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-
(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
fumarate 775287-00-8P, N-[2-[2-[4-[2-(Ethylmethylamino)ethyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-
trimethylbenzenesulfonamide fumarate 775287-02-0P,
N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-
methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775287-04-2P,
4-Methoxy-N-(1-methylethyl)-2,6-dimethyl-N-[2-[2-[4-[2-(1-
pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
fumarate 775287-06-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-
dimethyl-2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-
oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-08-6P,
N-[2-[2-[4-[(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-
trimethylbenzenesulfonamide difumarate 775287-10-0P,
4-Methoxy-N-[2-[2-[4-[2-(1-methyl-4-piperidinyl)ethyl]-1-piperidinyl]-2-
oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate
775287-12-2P, 4-Methoxy-N-[2-[2-[4-[2-(1-piperidinyl)ethyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate
775287-14-4P, 4-Methoxy-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]-N-methyl-2-(trifluoromethyl)benzenesulfona
mide trifluoroacetate 775287-16-6P, 4-Methoxy-N-[2-[2-[4-[2-(1-
methyl-4-piperazinyl)-2-oxoethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-
trimethylbenzenesulfonamide fumarate 775287-18-8P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(dimethylamino)methyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate
775287-20-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-
azetidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
fumarate 775287-22-4P, N,2,4,6-Tetramethyl-N-[2-[2-[4-(1-methyl-
4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
trifluoroacetate 775287-24-6P, N-Methyl-N-[2-[2-[4-(1-methyl-4-
piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-2-
(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-26-8P
, 4-Methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-
oxoethoxy]ethyl]-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate
775287-28-0P, N,2,4,6-Tetramethyl-N-[2-[2-[4-[2-(1-
pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
trifluoroacetate 775287-30-4P, 2,6-Dichloro-4-methoxy-N-methyl-N-
[2-[2-[4-(1-methyl-4-piperazinyl)-1-piperidinyl]-2-
oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-32-6P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate
775287-34-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-cyclopropyl-
1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
fumarate 775287-36-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-
(1,1-dimethylethyl)-1-piperazinyl]-1-piperidinyl]-2-
oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-38-2P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-
piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775287-40-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-methyl-1-
piperazinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
difumarate 775287-41-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-
(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide

775287-42-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-43-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-44-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-45-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-46-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-47-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-48-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-49-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-50-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-51-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-52-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-54-2P, N-[2-[2-(4,4'-Bipiperidin-1-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775287-55-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-56-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-59-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-60-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methylamino)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-61-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-62-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-63-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide 775287-64-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775287-66-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[1-oxo-2-(4-methyl-1-piperazinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-67-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide dihydrochloride 775287-68-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775288-89-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-06-9 CAPLUS

CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-08-1 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-18-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA

INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-20-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-22-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-24-1 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-23-0

CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-46-6 CAPLUS
CN Piperazine, 1-[3-(1-azetidinyl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-45-5
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-48-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-3-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-47-7
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-50-2 CAPLUS
CN Piperazine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-,

(2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-49-9
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-52-4 CAPLUS
CN Piperazine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-51-3
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-54-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-53-5
CMF C23 H35 N5 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-56-8 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho
xy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1

CRN 775285-55-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-58-0 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-57-9
CMF C24 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-60-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-59-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-62-6 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-61-5
CMF C26 H44 N4 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-64-8 CAPLUS
CN Piperazine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-63-7
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-66-0 CAPLUS
CN Piperazine, 1-(8-cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-65-9
CMF C28 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-68-2 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-67-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-70-6 CAPLUS
CN Piperazine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-69-3
CMF C28 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-72-8 CAPLUS
CN Piperazine, 1-(1-cyclopropyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-71-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-74-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-76-2 CAPLUS
CN Piperazine, 1-(1-ethyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-75-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-78-4 CAPLUS
CN Piperazine, 1-[1-(1,1-dimethylethyl)-4-piperidinyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-80-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-82-0 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-81-9
CMF C21 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-84-2 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-83-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-85-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-87-5 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-86-4
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-89-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-88-6
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-91-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-90-0
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-93-3 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-92-2
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-95-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-94-4
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-97-7 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-ethyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-96-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-99-9 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-98-8
CMF C23 H34 Cl2 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-01-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1,2,2,6,6-pentamethyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-00-5
CMF C28 H48 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-03-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate

(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-02-7
CMF C26 H45 N5 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-05-0 CAPLUS
CN Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-07-2 CAPLUS
CN Piperazine, 1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-06-1
CMF C27 H47 N5 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-09-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[8-(1-methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-08-3
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-11-8 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[3-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-oxopropyl]-4-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-10-7
CMF C27 H45 N5 O6 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-13-0 CAPLUS
CN Piperazine, 1-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-12-9
CMF C26 H45 N5 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-15-2 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-14-1
CMF C27 H42 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-17-4 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-16-3
CMF C26 H42 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-19-6 CAPLUS
CN 1-Piperazineethanamine, N,N-diethyl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-18-5
CMF C24 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-21-0 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-20-9
CMF C21 H31 Cl2 F N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-22-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-23-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-22-1
CMF C21 H31 Br Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-24-3 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775286-25-4 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-24-3
CMF C21 H31 Cl3 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-26-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-27-6 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-26-5
CMF C22 H34 Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-28-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-29-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-28-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-30-1 CAPLUS

CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 775286-31-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

OMe

RN 775286-32-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-31-2
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-34-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-33-4
CMF C23 H38 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-35-6 CAPLUS
CN Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775286-36-7 CAPLUS
CN Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-35-6
CMF C23 H33 N5 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-38-9 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N,β,β-tetramethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-37-8
CMF C25 H43 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-40-3 CAPLUS
CN 4-Piperidinemethanol, α-[(dimethylamino)methyl]-1-[[2-[[(4-methoxy-

2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-39-0
CMF C23 H39 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-42-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 775286-41-4
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-44-7 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-43-6
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-46-9 CAPLUS
CN Piperidine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-45-8
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-48-1 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-47-0
CMF C25 H41 N3 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-50-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (2E)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-49-2
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-52-7 CAPLUS
CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho

xy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 775286-51-6
CMF C26 H43 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-54-9 CAPLUS
CN Piperidine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-53-8
CMF C27 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-56-1 CAPLUS
CN Piperidine, 4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-55-0
CMF C27 H46 N4 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-58-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-57-2
CMF C25 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-60-7 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-59-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-62-9 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-61-8
CMF C27 H45 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-64-1 CAPLUS
CN 4,4'-Bipiperidine, 1-ethyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-63-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-66-3 CAPLUS
CN 4,4'-Bipiperidine, 1-cyclopropyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-65-2
CMF C27 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-68-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)

(CA INDEX NAME)

CM 1

CRN 775286-67-4
CMF C25 H41 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-70-9 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)-1,1-dimethylethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-69-6
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-72-1 CAPLUS

CN 4,4'-Bipiperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-71-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-74-3 CAPLUS
CN Piperidine, 4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-73-2
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-76-5 CAPLUS

CN 4,4'-Bipiperidine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-75-4
CMF C27 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-78-7 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,4-dichloro-3-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-77-6
CMF C23 H35 Cl2 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-80-1 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-79-8
CMF C24 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-82-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-81-2
CMF C21 H33 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-84-5 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-83-4
CMF C23 H35 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-86-7 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-pyrrolidinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-85-6
CMF C24 H39 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-88-9 CAPLUS
CN Piperidine, 4-[(4-ethyl-1-piperazinyl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-87-8
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-90-3 CAPLUS
CN Piperidine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-89-0
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-92-5 CAPLUS

CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho
xy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 775286-91-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-94-7 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 775286-93-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-96-9 CAPLUS

CN Piperidine, 4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-95-8
CMF C28 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775286-98-1 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-97-0
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-00-8 CAPLUS
CN 4-Piperidineethanamine, N-ethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-99-2
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-02-0 CAPLUS
CN 4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-01-9
CMF C25 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-04-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-

methylethyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-03-1
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-06-4 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-05-3
CMF C27 H45 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-08-6 CAPLUS
CN Piperidine, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-07-5
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-10-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-methyl-4-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-09-7
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-12-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-11-1
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-14-4 CAPLUS
CN Piperidine, 1-[[2-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-13-3
CMF C24 H36 F3 N3 O5 S



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-16-6 CAPLUS
CN Piperazine, 1-[[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]acetyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-15-5
CMF C26 H42 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-18-8 CAPLUS
CN 4-Piperidinemethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-17-7
CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-20-2 CAPLUS
CN Piperidine, 4-(1-azetidinylmethyl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-19-9
CMF C23 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-22-4 CAPLUS
CN 4,4'-Bipiperidine, 1-methyl-1'-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-21-3
CMF C25 H41 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-24-6 CAPLUS
CN 4,4'-Bipiperidine, 1-methyl-1'-[[2-[methyl[[2-(trifluoromethyl)phenyl]sulfonyl]amino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-23-5
CMF C23 H34 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-26-8 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-25-7
CMF C24 H36 F3 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-28-0 CAPLUS
CN Piperidine, 1-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-27-9
CMF C25 H41 N3 O4 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-30-4 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth

oxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-29-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-32-6 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-31-5
CMF C23 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-34-8 CAPLUS
CN Piperidine, 4-(4-cyclopropyl-1-piperazinyl)-1-[[2-[[(4-methoxy-2,6-

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-33-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-36-0 CAPLUS
CN Piperidine, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-35-9
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-38-2 CAPLUS

CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-37-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-40-6 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-methyl-1-piperazinyl)ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-39-3
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-41-7 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 775287-42-8 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-41-7
CMF C26 H43 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-43-9 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 775287-44-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-43-9
CMF C26 H43 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-45-1 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775287-46-2 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-45-1
CMF C28 H48 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-47-3 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 775287-48-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-47-3
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-49-5 CAPLUS

CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775287-50-8 CAPLUS
CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-49-5
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-51-9 CAPLUS
CN 4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 775287-52-0 CAPLUS
CN 4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-51-9
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-54-2 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-53-1
CMF C24 H39 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-55-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 775287-56-4 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-55-3
CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-59-7 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-58-6
CMF C27 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-60-0 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 775287-61-1 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



RN 775287-62-2 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-61-1
CMF C28 H46 N4 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 775287-63-3 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)



RN 775287-64-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-piperazinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-63-3
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-66-6 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-65-5

CMF C26 H42 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-67-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 775287-68-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775288-89-6 CAPLUS
CN 4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-β,β-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775288-88-5
CMF C27 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 633698-34-7P, [2-[[(2,4-Dichloro-3-methylphenyl)sulfonyl]methylamino]ethoxy]acetic acid 766558-33-2P, [2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetic acid 766558-35-4P, [2-[[(2,4,6-Trimethylphenyl)sulfonyl]methylamino]ethoxy]acetic acid 775287-71-3P, [2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]ethylamino]ethoxy]acetic acid 775287-74-6P, [2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](1-

methylethyl)amino]ethoxy]acetic acid 775287-77-9P, [2-[N-Cyclopropyl-N-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetic acid 775287-82-6P, [2-[[(2,6-Dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetic acid 775287-84-8P, [2-[[(2,4-Dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetic acid 775287-87-1P, [2-[[[2-(Trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetic acid 775287-88-2P, [2-[[[4-Methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetic acid 775288-66-9P, 4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 775288-67-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(1-piperazinyl)ethoxy]ethyl]benzenesulfonamide 775288-69-2P, 4-[3-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl]-1-piperidinecarboxylic acid phenylmethyl ester 775288-70-5P, 4-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 775288-73-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-nitro-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775288-74-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(3-hydroxypropyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-75-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-76-1P, 1'-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4,4'-bipiperidine-1-carboxylic acid 1,1-dimethylethyl ester 775288-77-2P, [2-[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]ethyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-78-3P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]carbamic acid 1,1-dimethylethyl ester 775288-79-4P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-82-9P, 4-[[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-1-piperazinecarboxylic acid phenylmethyl ester 775288-83-0P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid ethyl ester 775288-84-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 633698-34-7 CAPLUS
CN Acetic acid, [2-[[(2,4-dichloro-3-methylphenyl)sulfonyl]methylamino]ethoxy]- (9CI) (CA INDEX NAME)



RN 766558-33-2 CAPLUS

CN Acetic acid, 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]- (CA INDEX NAME)



RN 766558-35-4 CAPLUS
CN Acetic acid, [2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]-
(9CI) (CA INDEX NAME)



RN 775287-71-3 CAPLUS
CN Acetic acid, [2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy
]- (9CI) (CA INDEX NAME)



RN 775287-74-6 CAPLUS
CN Acetic acid, [2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-
methylethyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 775287-77-9 CAPLUS
CN Acetic acid, [2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]
ethoxy]- (9CI) (CA INDEX NAME)



RN 775287-82-6 CAPLUS
CN Acetic acid, [2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]- (9CI) (CA INDEX NAME)



RN 775287-84-8 CAPLUS
CN Acetic acid, [2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]- (9CI) (CA INDEX NAME)



RN 775287-87-1 CAPLUS
CN Acetic acid, [2-[methyl[[2-(trifluoromethyl)phenyl]sulfonyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 775287-88-2 CAPLUS
CN Acetic acid, [2-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]- (9CI) (CA INDEX NAME)



RN 775288-66-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-67-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775288-69-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 775288-70-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-73-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(6-nitro-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 775288-74-9 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775288-75-0 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-76-1 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-77-2 CAPLUS
CN Carbamic acid, [2-[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OBu-t

RN 775288-78-3 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino

]ethoxy]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-79-4 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-82-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-83-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 775288-84-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:800854 CAPLUS
DOCUMENT NUMBER: 141:314016
TITLE: Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1606288	A1	20051221	EP 2004-742333	20040324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

BR 2004008689	A	20060328	BR 2004-8689		20040324
CN 1764661	A	20060426	CN 2004-80007762		20040324
JP 2006521333	T	20060921	JP 2006-505749		20040324
IN 2005DN03814	A	20070817	IN 2005-DN3814		20050826
NO 2005004361	A	20051101	NO 2005-4361		20050920
PRIORITY APPLN. INFO.:			FR 2003-3602	A	20030325
			FR 2003-4530	A	20030411
			WO 2004-FR723	A	20040324

OTHER SOURCE(S): MARPAT 141:314016
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1, R2, R3 = independently H, halo, alkyl, alkoxy, CF3, OCF3; Y = CH2CONHCH2, saturated alkylene chain interrupted by O or unsatn.; A = a bond, (CH2)m; R = saturated N-containing heterocycle selected from pyrrolidine, morpholine, piperidine, quinuclidine, tropane, or dialkylamino, etc.; X = (CH2)p; m, p = independently 2-3; and their acid addition salts] were prepared as Bradykinin B1 receptor antagonists for treatment of pain, inflammation. A 4-step synthesis for benzenesulfonamide II•2TFA is given. Selected I inhibited the second phase of licking response by 40 to 43% in a test of pain induced by formalin in mice. I inhibited Kallidin (a homolog of bradykinin)-induced contraction of isolated human umbilical vein, with a pKB > 7.

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-09-2 CAPLUS

CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



IT 766558-11-6P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-11-6 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bistrifluoroacetate 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N-methyl-2,4,6-trimethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-14-9P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bistrifluoroacetate 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bistrifluoroacetate 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bistrifluoroacetate 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(dimethylamino)propyl]piperazine bistrifluoroacetate 766558-26-3P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bistrifluoroacetate 766558-28-5P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 766558-30-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-06-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-08-1 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-14-9 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-18-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-20-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-22-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-24-1 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-23-0
CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-,

(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-33-2P, [2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetic acid 766558-35-4P, [2-[[(2,4,6-Trimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-33-2 CAPLUS
CN Acetic acid, 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]- (CA INDEX NAME)



RN 766558-35-4 CAPLUS
CN Acetic acid, [2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



IT 766558-13-8P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-

piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-
dimethylbenzenesulfonamide
RL: PUR (Purification or recovery); RCT (Reactant); PREP
(Preparation); RACT (Reactant or reagent)
(preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists
for treatment of pain and inflammation)
RN 766558-13-8 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-
dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD

```
 NEWS 16  JAN 02  STN pricing information for 2008 now available
 NEWS 17  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS 18  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS 19  JAN 28  MARPAT searching enhanced
 NEWS 20  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 21  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 22  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 23  FEB 08  STN Express, Version 8.3, now available
 NEWS 24  FEB 20  PCI now available as a replacement to DPCI
 NEWS 25  FEB 25  IFIREF reloaded with enhancements
 NEWS 26  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 27  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:40:03 ON 14 MAR 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:40:17 ON 14 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 MAR 2008  HIGHEST RN 1007849-81-1
DICTIONARY FILE UPDATES:  13 MAR 2008  HIGHEST RN 1007849-81-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
```

predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10549546\10549546n.str



chain nodes :
7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6 14
chain bonds :
6-7 7-8 8-9 9-10 10-11 11-12 12-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 12-13 12-14
exact bonds :
6-7 8-9 9-10 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:40:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   4680 TO ITERATE

42.7% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 89498 TO 97702
PROJECTED ANSWERS: 4 TO 370

L2 4 SEA SSS SAM L1

=> d scan

L2 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)
MF C27 H45 N3 O5 S . C4 H4 O4

CM 1





CM 2

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(6-nitro-3-pyridinyl)- (9CI)
MF C23 H31 N5 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)
MF C25 H41 N3 O5 S . C4 H4 O4

CM 1

PAGE 1-A



PAGE 2-A



CM 2

Double bond geometry as shown.



L2 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperidine, 1-[[2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)
MF C27 H44 N4 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full
FULL SEARCH INITIATED 10:40:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 94235 TO ITERATE

100.0% PROCESSED 94235 ITERATIONS 292 ANSWERS
SEARCH TIME: 00.00.02

L3 292 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 10:41:05 ON 14 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Mar 2008 VOL 148 ISS 12
FILE LAST UPDATED: 13 Mar 2008 (20080313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d l4 1-3 ibib

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1392027 CAPLUS
DOCUMENT NUMBER: 148:54908
TITLE: Preparation of spirocyclic sulfonamides and related compounds as modulators of bradykinin receptor activity
INVENTOR(S): Hodgetts, Kevin J.; Ihle, David C.; Li, Guiying; Ge, Ping; Chenard, Bertrand L.; Wustrow, David J.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 82pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007140383	A2	20071206	WO 2007-US69918	20070530
WO 2007140383	A3	20080124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-803419P P 20060530
OTHER SOURCE(S): MARPAT 148:54908

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857596 CAPLUS
DOCUMENT NUMBER: 141:350198
TITLE: Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087700	A1	20041014	WO 2004-FR723	20040324

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
FR 2853648	A1	20041015	FR 2003-4530	20030411
FR 2853648	B1	20060818		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
EP 1606288	A1	20051221	EP 2004-742333	20040324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

BR 2004008689	A	20060328	BR 2004-8689	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
IN 2005DN03814	A	20070817	IN 2005-DN3814	20050826
US 2006178360	A1	20060810	US 2005-549546	20050914
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.: FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:350198
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:800854 CAPLUS
DOCUMENT NUMBER: 141:314016
TITLE: Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
WO 2004087700	A1	20041014	WO 2004-FR723	20040324

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
CN 1764661	A	20060426	CN 2004-80007762	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
IN 2005DN03814	A	20070817	IN 2005-DN3814	20050826
NO 2005004361	A	20051101	NO 2005-4361	20050920
PRIORITY APPLN. INFO.:			FR 2003-3602 A	20030325
			FR 2003-4530 A	20030411
			WO 2004-FR723 A	20040324

OTHER SOURCE(S): MARPAT 141:314016

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>